Systemic Sclerosis (SSc)
3
Pipeline Programs
3
Companies
4
Clinical Trials
4 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 3 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
T-TherapeuticsUK - Cambridge
2 programs1
Sodium ThiosulfatePhase 21 trial
Apollo Neuro DeviceN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
2029
T-TherapeuticsSodium Thiosulfate
Zura BioTibulizumab
argenxEfgartigimod PH20 SC
T-TherapeuticsApollo Neuro Device
Clinical Trials (4)
Total enrollment: 241 patients across 4 trials
Intralesional Injection of STS in Treatment of Calcinosis
Start: Mar 2025Est. completion: May 2029
Phase 2Recruiting
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Start: Feb 2025Est. completion: Jan 2028
Phase 2Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
Start: Nov 2024Est. completion: Jun 202781 patients
Phase 2Recruiting
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
Start: Jan 2025Est. completion: Sep 2028160 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 actively recruiting trials targeting 241 patients
3 companies competing in this space